Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a ...

Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...

In a tough labor market where layoffs continue, some are considering—or even moving—from industry to academia, according to a ...

Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back ...

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.

Artificial intelligence won’t replace people in biopharma, but it is infiltrating every step of drug development, including ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

When Sanofi announced last week that it plans to sell a 50% controlling stake of Opella, its consumer helath business, the ...

J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which ...